Literature DB >> 32606177

A Comparison of 18F-FDG-PET/MRI and 18F-FDG-PET/CT in the Cancer Staging of Locoregional Lymph Nodes.

David Slouka1, Jiri Krcal1, Tomas Kostlivy1, Petr Hrabacka1, Alena Skalova2, Hynek Mirka3, Ondrej Topolcan4, Radek Kucera5.   

Abstract

AIM: The aim of the study was to evaluate the yields of 2-deoxy-2-[18F]-fluoro-D-glucose positron-emission tomography/magnetic resonance imaging (18F-FDG-PET/MRI) and 18F-FDG-PET/computed tomography (CT) for the detection of metastatic involvement of locoregional neck nodes in patients with head and neck malignancy. PATIENTS AND METHODS: A total of 90 patients (66 men and 24 women) met the inclusion criteria. Preoperative staging was performed: 53 examinations using PET/CT and 37 using PET/MRI.
RESULTS: For PET/MRI, the study demonstrated a sensitivity of 89%, specificity of 64%, positive predictive value of 85%, and negative predictive value of 70%; PET/CT had a sensitivity of 95%, specificity 47%, positive predictive value of 82%, and negative predictive value of 78%.
CONCLUSION: Both methods have a high yield in N-clinical staging with statistically insignificant differences. We assume PET/MRI to be the first-choice method in organ-targeted examinations, for pediatric patients and repeat examinations. In cases of MRI contraindication, PET/CT can be used with no impact on the quality of care. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Head and neck tumours; PET/CT; PET/MRI; cancer staging; hybrid imaging; lymph node

Mesh:

Substances:

Year:  2020        PMID: 32606177      PMCID: PMC7439898          DOI: 10.21873/invivo.12002

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  18 in total

Review 1.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

2.  Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer.

Authors:  K Kubiessa; S Purz; M Gawlitza; A Kühn; J Fuchs; K G Steinhoff; A Boehm; O Sabri; R Kluge; T Kahn; P Stumpp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-29       Impact factor: 9.236

3.  3T MRI evaluation of large nerve perineural spread of head and neck cancers.

Authors:  Justin Baulch; Mitesh Gandhi; Jennifer Sommerville; Ben Panizza
Journal:  J Med Imaging Radiat Oncol       Date:  2015-07-14       Impact factor: 1.735

Review 4.  History and future technical innovation in positron emission tomography.

Authors:  Terry Jones; David Townsend
Journal:  J Med Imaging (Bellingham)       Date:  2017-03-31

5.  [PET/CT and PET/MRI in Head and Neck Cancer].

Authors:  Jirka Grosse; Dirk Hellwig
Journal:  Laryngorhinootologie       Date:  2020-01-14       Impact factor: 1.057

6.  PET-MRI in the head and neck area: challenges and new directions.

Authors:  J A Castelijns
Journal:  Eur Radiol       Date:  2011-06-23       Impact factor: 5.315

Review 7.  Recent changes in the epidemiology of head and neck cancer.

Authors:  Maria Paula Curado; Mia Hashibe
Journal:  Curr Opin Oncol       Date:  2009-05       Impact factor: 3.645

8.  The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond.

Authors:  Thomas Beyer; Lutz S Freudenberg; Johannes Czernin; David W Townsend
Journal:  Insights Imaging       Date:  2011-03-25

9.  Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments.

Authors:  Christoph Evers; Christian Ostheimer; Frank Sieker; Dirk Vordermark; Daniel Medenwald
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

10.  Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/MR versus PET/CT.

Authors:  Arthur Varoquaux; Olivier Rager; Antoine Poncet; Bénédicte M A Delattre; Osman Ratib; Christoph D Becker; Pavel Dulguerov; Nicolas Dulguerov; Habib Zaidi; Minerva Becker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.